PL4253376T3 - Sól i postać krystaliczna pochodnej heterocyklicznej zawierającej azot, sposób jej otrzymywania i jej zastosowanie - Google Patents

Sól i postać krystaliczna pochodnej heterocyklicznej zawierającej azot, sposób jej otrzymywania i jej zastosowanie

Info

Publication number
PL4253376T3
PL4253376T3 PL21897144.8T PL21897144T PL4253376T3 PL 4253376 T3 PL4253376 T3 PL 4253376T3 PL 21897144 T PL21897144 T PL 21897144T PL 4253376 T3 PL4253376 T3 PL 4253376T3
Authority
PL
Poland
Prior art keywords
nitrogen
salt
preparation
application
crystal form
Prior art date
Application number
PL21897144.8T
Other languages
English (en)
Inventor
Qingxin Liu
Linsong Guo
Original Assignee
Shanghai Hansoh Biomedical Co., Ltd.
Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Hansoh Biomedical Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Co., Ltd. filed Critical Shanghai Hansoh Biomedical Co., Ltd.
Publication of PL4253376T3 publication Critical patent/PL4253376T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
PL21897144.8T 2020-11-26 2021-11-26 Sól i postać krystaliczna pochodnej heterocyklicznej zawierającej azot, sposób jej otrzymywania i jej zastosowanie PL4253376T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202011354289 2020-11-26
CN202111389216 2021-11-22
PCT/CN2021/133653 WO2022111644A1 (zh) 2020-11-26 2021-11-26 含氮杂环类衍生物的盐、晶型及其制备方法和应用

Publications (1)

Publication Number Publication Date
PL4253376T3 true PL4253376T3 (pl) 2025-12-01

Family

ID=81753731

Family Applications (1)

Application Number Title Priority Date Filing Date
PL21897144.8T PL4253376T3 (pl) 2020-11-26 2021-11-26 Sól i postać krystaliczna pochodnej heterocyklicznej zawierającej azot, sposób jej otrzymywania i jej zastosowanie

Country Status (12)

Country Link
US (1) US20240325394A1 (pl)
EP (1) EP4253376B1 (pl)
JP (1) JP2023551006A (pl)
CN (1) CN116490188A (pl)
AU (1) AU2021386339A1 (pl)
CA (1) CA3200164A1 (pl)
PL (1) PL4253376T3 (pl)
RS (1) RS67327B1 (pl)
SM (1) SMT202500386T1 (pl)
TW (1) TW202229278A (pl)
WO (1) WO2022111644A1 (pl)
ZA (1) ZA202306437B (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115052870B (zh) * 2020-08-02 2024-02-20 上海喆邺生物科技有限公司 一种芳香类化合物及其在抗肿瘤药物中的应用
KR20230094198A (ko) 2020-09-23 2023-06-27 에라스카, 아이엔씨. 3환식 피리돈 및 피리미돈
WO2022133345A1 (en) 2020-12-18 2022-06-23 Erasca, Inc. Tricyclic pyridones and pyrimidones

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190272A1 (ar) * 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
EP3679040B1 (en) * 2017-09-08 2022-08-03 Amgen Inc. Inhibitors of kras g12c and methods of using the same
AU2019262589B2 (en) * 2018-05-04 2022-07-07 Amgen Inc. KRAS G12C inhibitors and methods of using the same
CA3100390A1 (en) * 2018-06-12 2020-03-12 Amgen Inc. Kras g12c inhibitors encompassing piperazine ring and use thereof in the treatment of cancer
PH12021552922A1 (en) * 2019-05-21 2022-04-04 Amgen Inc Solid state forms
US12252486B2 (en) * 2019-05-21 2025-03-18 Amgen Inc. Solid state forms
KR20220010542A (ko) * 2019-05-21 2022-01-25 인벤티스바이오 컴퍼니 리미티드 헤테로 고리 화합물, 이의 제조 방법 및 용도
JP7584451B2 (ja) * 2019-05-29 2024-11-15 上▲海▼翰森生物医▲薬▼科技有限公司 窒素含有複素環系誘導物レギュレーター、その製造方法及び使用
CN112390796B (zh) * 2019-08-19 2023-06-27 贝达药业股份有限公司 Kras g12c抑制剂及其在医药上的应用
WO2021143693A1 (zh) * 2020-01-13 2021-07-22 苏州泽璟生物制药股份有限公司 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用
WO2021185233A1 (en) * 2020-03-17 2021-09-23 Jacobio Pharmaceuticals Co., Ltd. Kras mutant protein inhibitors
WO2021236920A1 (en) * 2020-05-20 2021-11-25 Teva Pharmaceuticals International Gmbh Solid state forms of amg-510 and process for preparation thereof

Also Published As

Publication number Publication date
CN116490188A (zh) 2023-07-25
ZA202306437B (en) 2025-09-25
AU2021386339A9 (en) 2025-01-09
CA3200164A1 (en) 2022-06-02
WO2022111644A1 (zh) 2022-06-02
SMT202500386T1 (it) 2025-11-10
EP4253376B1 (en) 2025-07-30
RS67327B1 (sr) 2025-11-28
EP4253376A4 (en) 2024-12-18
JP2023551006A (ja) 2023-12-06
EP4253376C0 (en) 2025-07-30
US20240325394A1 (en) 2024-10-03
TW202229278A (zh) 2022-08-01
EP4253376A1 (en) 2023-10-04
AU2021386339A1 (en) 2023-07-06

Similar Documents

Publication Publication Date Title
RS67327B1 (sr) So i kristalni oblik heterocikličnih derivata koji sadrže azot, postupak njihove pripreme i primene
EP4328225A4 (en) HETEROCYCLIC DERIVATIVE INHIBITOR AND ITS PREPARATION METHOD AND APPLICATION
EP4273136A4 (en) NITROGEN-CONTAINING BRIDGED HETEROCYCLIC COMPOUND, METHOD OF PREPARING THE SAME AND MEDICAL USE THEREOF
IL316662B1 (en) Method for preparing nicotinamide ribofuranoside salts, nicotinamide ribofuranoside salts as such, and uses thereof
GB202307487D0 (en) Method for preparing nitrogen-containing heterocyclic compound and derivative thereof by means of enzymatic-chemical cascade method
EP3763713A4 (en) CRYSTAL FORM AND SALT FORM OF A PYRIDOIMIDAZOLE COMPOUND AND THE METHOD FOR MANUFACTURING IT
EP4349828A4 (en) NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PRODUCTION PROCESS THEREOF AND USE THEREOF
EP3912976A4 (en) SALT OF AN EGFR INHIBITOR, CRYSTALLINE FORM AND METHOD FOR PREPARING THEREOF
EP4112052A4 (en) USE OF AN N-SUBSTITUTED PYRIDYLBENZISOSELENAZOLONE COMPOUND
IL288348B2 (en) Method for synthesizing a furoimidazopyridine compound, a crystalline form of a furoimidazopyridine compound, and a crystalline form of a salt thereof
EP4215244A4 (en) Triazine compound salt, crystal form thereof, and production method therefor
IL289231A (en) Salts of compounds, their crystalline forms and their uses
IL314594A (en) Heterocyclic compounds and methods of use
EP4293021A4 (en) SALT OF A NITROGEN-CONTAINING CONDENSED HETEROCYCLIC COMPOUND OR CRYSTAL FORM THEREOF AND PROCESS FOR PREPARING THE SAME, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF
EP4353725A4 (en) Salt and crystal form of a pyrazole-containing polycyclic derivative, production process therefor, and use thereof
PT3939977T (pt) Cristal de composto de amida heterocíclica e método de produção do mesmo
HK40121885A (en) Pharmaceutically acceptable salt and crystal form of nitrogen-containing bridge heterocyclic derivative, and method for preparing same
EP4219476A4 (en) SALT OF A COMPOUND CONTAINING ARYLAMINOCHINAZOLINE, PROCESS FOR PREPARING THE SAME AND USE THEREOF
HK40067527B (zh) 杂环类化合物的晶型及其制备方法和应用
ZA202108765B (en) Pyridone derivative crystal form and preparation method and application therefor
EP4335850A4 (en) SALT FORM OF A PYRROLOTRIAZINE COMPOUND, CRYSTAL FORM THEREOF AND METHOD OF PREPARING THE SAME
EP4353729A4 (en) POLYMORPH OF AN IMIDAZOLIDINONE COMPOUND, METHOD FOR PREPARING THE SAME AND USE THEREOF
EP4190402A4 (en) HETEROCYCLIC COMPOUND CONTAINING NITROGEN OR SALT THEREOF, APPLICATION THEREOF, AND INTERMEDIATE THEREOF
AU2021354821A9 (en) Crystal form of pyrrolo heterocyclic derivative and preparation method therefor
EP4269408A4 (en) CRYSTAL FORM OF A COMPOUND AND METHOD OF PREPARING IT AND USE THEREOF